Acrux Limited ACR

Acrux is a successful Australian pharmaceutical company that develops innovative drugs for the global market. It recently announced its new strategy to enter the final, phase III clinical trial, stage of development for a Female Testosterone product. This continues the company's heritage in designing and developing patient-preferred drug delivery systems and it address a large unmet patient need. The unmet need is Hypoactive Sexual Desire Disorder (HSDD) or, in common English low libido or low s

The Australian market has recently experienced a mixed performance, with materials dragging down the indices while energy stocks showed resilience amid shifting global economic sentiments. In this context, growth companies with high insider ownership can be particularly appealing as they often indicate strong internal confidence and alignment of interests, making them worth considering in today's fluctuating market environment.